Abstract: This invention is directed to methods for the production of immunogenic granular particles. In certain embodiments, the invention is directed to methods and products for the production of immunogenic granular particles produced in ciliates. In certain embodiments, the invention is directed to compositions comprising Granule lattice protein/Antigen(Grl/Ag) fusion polypeptides.

Abstract: Methods for aiding in the diagnosis of disorders including, but not limited to, PDDs (Pervasive Development Disorders), Dysautonomic disorders, Parkinson's disease and SIDS (Sudden Infant Death Syndrome). In one aspect, a diagnosis method comprises analyzing a stool sample of an individual for the presence of a biological marker (or marker compound) comprising one or more pathogens, which provides an indication of whether the invidual has, or can develop, a disorder including, but not limited to, a PDD, Dysautonomia, Parkinsons disease and SIDS. Preferably, the presence of one or more pathogens is determined using a stool immunoassay to determine the presence of antigens in a stool sample, wherein such antigens are associated with one or more pathogens including, but not limited to, Giardia, Cryptosporidium, E. histolytica, C. difficile, Adenovirus, Rotavirus or H. pylori.

Abstract: A method and system for achieving a gas-liquid mass transfer includes delivering into a compartment of a container a liquid, the liquid having an exposed top surface disposed within the compartment. A stream of a gas is passed over the top surface of the liquid so that the stream of gas produces turbulence on the top surface that is sufficient to achieve the gas-liquid mass transfer. In one embodiment the liquid is a culture that includes cells or microorganisms and the mass transfer functions to oxygenate the culture sufficient to sustain the cells or microorganisms.

Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Abstract: The present invention relates to a polypeptide that is capable of inhibiting transcription and expression of fatty acid synthase (FAS) and the polynucleotides encoding therefor, as well as the use thereof. Specifically, the present invention relates to a polypeptide that can inhibit the transcription and expression of FAS at the molecular level, the cellular level and in vivo, and can therefore prevent the overexpression of FAS. Said polypeptide and related peptidomimetics, including functional fragments or functional varieties thereof, and the genes encoding therefor, can be widely used in preventing and treating tumors such as liver cancer, and diseases closely related to the metabolism of fatty acid synthase, such as fatty liver and obesity.

Abstract: The present disclosure provides a non-naturally occurring microorganism comprising: one or more polynucleotides encoding one or more enzymes in a pathway that produces acetyl-CoA; one or more polynucleotides encoding one or more enzymes in a pathway that catalyze a conversion of cytosolic acetyl-CoA to 2-propanol; one or more polynucleotides encoding one or more enzymes in a pathway that catalyze a conversion of dihydroxyacetone-phosphate to 1-propanol and/or 1,2-propanediol, wherein the microorganism has reduced levels of pyruvate decarboxylase enzymatic activity (e.g., the microorganism comprises a disruption of one or more enzymes that decarboxylate pyruvate and/or a disruption of one or more transcription factors of one or more enzymes that decarboxylate pyruvate), and wherein the microorganism is capable of growing on a C6 sugar as a sole carbon source under anaerobic conditions.

Abstract: The present disclosure provides a non-naturally occurring microorganism comprising: one or more polynucleotides encoding one or more enzymes in a pathway that produces acetyl-CoA; one or more polynucleotides encoding one or more enzymes in a pathway that catalyze a conversion of crotonyl alcohol, 5-hydroxy-3-ketovaleryl-CoA, 3-ketopent-4-enoyl-CoA, or 3,5-ketovaleryl-CoA to butadiene; one or more polynucleotides encoding one or more enzymes in a pathway that catalyze a conversion of dihydroxyacetone-phosphate to 1-propanol and/or 1,2-propanediol, wherein the microorganism has reduced levels of pyruvate decarboxylase enzymatic activity (e.g., the microorganism comprises a disruption of one or more enzymes that decarboxylate pyruvate and/or a disruption of one or more transcription factors of one or more enzymes that decarboxylate pyruvate), and wherein the microorganism is capable of growing on a C6 sugar as a sole carbon source under anaerobic conditions.

Abstract: A process for capturing or concentrating microorganisms for detection or assay comprises (a) providing a concentration device comprising a sintered porous polymer matrix comprising at least one concentration agent that comprises an amorphous metal silicate and that has a surface composition having a metal atom to silicon atom ratio of less than or equal to 0.5, as determined by X-ray photoelectron spectroscopy (XPS); (b) providing a sample comprising at least one microorganism strain; and (c) contacting the concentration device with the sample such that at least a portion of the at least one microorganism strain is bound to or captured by the concentration device.

Abstract: A method of producing isoprene is disclosed. In one embodiment, the method comprises the steps of obtaining a host transgenic microorganism and observing the production of isoprene by the microorganism. In another embodiment, the invention is a transgenic host microorganism for producing isoprene.

Abstract: The present disclosure generally relates to microorganisms that comprise one or more polynucleotides coding for enzymes in one or more pathways that catalyze a conversion of a fermentable carbon source to butadiene. Also provided are methods of using the microorganisms in industrial processes including, for use in the production of butadiene and products derived therefrom.

Abstract: A method for producing organic-inorganic composite materials includes at least one biomineralising protein and/or polypeptide-encoding recombinant polynucleotide being introduced into at least one host cell, preferably from the class of slime moulds, and the expressed protein and/or polypeptide influencing the formation of inorganic particles in an extracellular matrix of the host cell.

Abstract: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

Abstract: The present invention relates to polynucleotides from Cochliobolus heterostrophus C5, Cyanothece sp. CCY0110, Mycocentrospora acerin and Hyaloperonospora parasitica, which code for desaturases and which can be employed for the recombinant production of polyunsaturated fatty acids. The invention furthermore relates to vectors, host cells and transgenic nonhuman organisms which comprise the polynucleotides according to the invention, and to the polypeptides encoded by the polynucleotides. The invention furthermore relates to antibodies against the polypeptides according to the invention. Finally, the invention also relates to production processes for the polyunsaturated fatty acids and for oil, lipid and fatty acid compositions and to their use as drugs, cosmetics, foodstuffs, feedstuffs, preferably fish food, or food supplements.

Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.

Abstract: Disclosed are methods and compositions related to ONC-T18, D4-desaturases, D5 elongases, their isolation, characterization, production, identification, and use for fatty acid production, as well as organisms containing these compositions and organisms expressing them.

Abstract: The invention relates to a method for controlling the proliferation of Pseudomonas, with the exception of the treatment methods applied to the human or animal body, characterized in that it uses protozoa of the Willaertia magna species, and also to a disinfecting agent containing such protozoa.

Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1? and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

Abstract: Engineered multivalent and multispecific binding proteins that bind TNF? and IL-13, TNF? and PGE2, or TNF? and NGF are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

Abstract: In one aspect, the present invention relates to a method of identifying compounds useful in modifying the activity of Aldolase.

Abstract: Provided are multispecific binding proteins and methods for using these multispecific binding proteins to modulate the activation state of immune cells, such as T-cells (e.g., cytotoxic T-cells). Also provided are methods of modulating an immune response (e.g., cell killing by cytotoxic T-cells) in a subject (e.g., a human subject). Also provided are nucleic acids, expression vectors and host cells encoding the multispecific binding proteins.

Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.

Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

Abstract: In order to thoroughly solve existing vinasse problems, in particular in production of bioethanol from plant raw materials, a method is proposed for producing feedstuffs from crustaceans of the genus Artemia (brine shrimp) or Copepoda (oar-footed crustaceans) or Daphnia (water fleas) or from microbes in the form of rotifers or protozoa, the method being characterized in that the crustacean/microbe cultures are fed at least partially with vinasse, preferably thin vinasse, in particular from bioethanol production, and with yeasts contained in the vinasse. At the same time, a method for processing vinasse is provided, the method accordingly being characterized in that the vinasse is used as feed for crustacean/microbe cultures and/or for algae cultures in order to at least partially decompose the yeasts contained in the vinasse.

Abstract: Various 1-alkenes, including 1-nonadecene and 1-octadecene, are synthesized by the engineered microorganisms and methods of the invention. In certain embodiments, the microorganisms comprise a recombinant alpha-olefin-associated enzyme. This enzyme may be expressed in combination with a recombinant alkene synthase pathway-related gene. The engineered microorganisms may be photosynthetic microorganisms such as cyanobacteria.

Abstract: A heat exchanger system includes a heat exchanger having a body plate with a first side face and an opposing second side face, the body plate bounding a fluid channel disposed between the opposing side faces and extending between an inlet port and an outlet port, and a first side plate having an inside face. A flexible first bag includes of one or more sheets of polymeric material, the first bag bounding a fluid pathway that extends between a fluid inlet and a fluid outlet, the first bag being removably retained between the body plate and the first side plate so that at least a portion of the first bag rests against the first side face of the body plate when the fluid pathway of the first bag is filled with a fluid.

Abstract: Methods for aiding in the diagnosis of disorders including, but not limited to, PDDs (Pervasive Development Disorders), Dysautonomic disorders, Parkinson's disease and SIDS (Sudden Infant Death Syndrome). In one aspect, a diagnosis method comprises analyzing a stool sample of an individual for the presence of a biological marker (or marker compound) comprising one or more pathogens, which provides an indication of whether the individual has, or can develop, a disorder including, but not limited to, a PDD, Dysautonomia, Parkinsons disease and SIDS. Preferably, the presence of one or more pathogens is determined using a stool immunoassay to determine the presence of antigens in a stool sample, wherein such antigens are associated with one or more pathogens including, but not limited to, Giardia, Cryptosporidium, E. histolytica, C. difficile, Adenovirus, Rotavirus or H. pylori.

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.

Abstract: The present disclosure generally relates to microorganisms (e.g., non-naturally occurring microorganisms) that comprise one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion of a carbon source (e.g., a fermentable carbon source) to butadiene and succinate and the use of such microorganisms for the production of butadiene and succinate.

Abstract: A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.

Abstract: The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein-coding gene known as LmPDI which has two regions that are identical to the sequence (Cys-Gly-His-Cys) of the potential active site of the protein disulphide isomerase (PDI). The LmPDI protein is predominantly expressed in the most virulent isolates of the parasite. Said protein forms a novel therapeutic target for developing anti-leishmaniasis medicaments and a novel element that can be used in the composition of immunogenic, and possibly vaccinating, preparations which are intended to protect a human or animal host against Leishmania.

Abstract: The present invention provides compositions and methods for producing ethanol wherein the amount of CO2 by-product is reduced during the fermentation process. The invention includes the use of oxidized lignin during the fermentation process.

Abstract: The present invention relates to recombinant cells and microorganisms of the phylum Labyrinthulomycota and their use in heterologous protein production. Novel promoter, terminator, and signal sequences for efficient production and, optionally, secretion of polypeptides from recombinant host cells and microorganisms are also encompassed by the present invention.

Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.

Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

Abstract: A container system includes a bag having of one or more sheets of flexible polymeric material, the bag having an interior surface at least partially bounding a chamber that is adapted to hold a fluid. A sparger is secured to the interior surface of the bag so that a compartment is formed between the interior surface of the bag and the sparger. At least a portion of the sparger includes a sparging sheet formed from a flexible sheet of a gas permeable material. A tubular port or tube is coupled with the bag so that a passage bounded by the tubular port or tube communicates with the compartment.

Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Abstract: This invention is directed to methods for recombinant polypeptide production and, in particular, methods and products for the production of recombinant polypeptides in ciliates.

Abstract: The NonA alkene synthase in Synechococcus sp. displays selective synthesis of 1-nonadecene. Heterologous recombination of a domain, i.e. the acyl binding domain, with other acyl binding proteins, affects acyl substrate chain-length binding selectivity and therefore the chain-length of the synthesized 1-alkenes. Compositions and methods are provided to selectively synthesize 1-alkenes of various chain lengths.

Abstract: The present invention relates to polynucleotides from Ostreococcus lucimarinus which code for desaturases and elongases and which can be employed for the recombinant production of polyunsaturated fatty acids. The invention furthermore relates to vectors, host cells and transgenic nonhuman organisms which comprise the polynucleotides, and to the polypeptides encoded by the polynucleotides. Finally, the invention also relates to production processes for the polyunsaturated fatty acids and for oil, lipid and fatty acid compositions.

Abstract: Disclosed herein are novel proteins that have reduced binding to the interleukin-7 receptor, compositions containing such proteins, and methods of using the same.

Abstract: To provide a transformation method for producing a stramenopile organism having an improved unsaturated fatty acid production capability by disrupting a gene of the stramenopile organism or inhibiting the expression of the gene in a genetically engineering manner. [Solution] A method for transforming a stramenopile organism, which comprises disrupting a gene of the stramenopile organism or inhibiting the expression of the gene in a genetically engineering manner, and which is characterized in that the stramenopile organism is selected from Thraustochytrium aureum, Parietichytrium sarkarianum, Thraustochytrium roseum and Parietichytrium sp. and the gene to be disrupted or of which the expression is to be inhibited is a gene associated with the biosynthesis of a fatty acid.

Abstract: The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides which inhibit multimerization of a receptor complex comprising an IL-17R family member. Related PLAD-binding polypeptides, chimeric proteins, conjugates, nucleic acids, vectors, host cells, and methods are provided herein.

Abstract: A treatment agent for salt-containing organic waste liquid, the treatment agent including: Scuticociliatida, wherein the treatment agent treats salt-containing organic waste liquid; and a treatment method for salt-containing organic waste liquid, the treatment method including: bringing Scuticociliatida and salt-containing organic waste liquid into contact with each other to treat the salt-containing organic waste liquid.

Abstract: The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids.

Abstract: A method for processing a fluid includes sparging a fluid within the compartment of a container with an initial gas so that the initial gas passes through a portion of the fluid to form a humid gas within the compartment. The humid gas is passed out of the compartment of the container and into a flexible condenser bag. The humid gas within the condenser bag is cooled so as to separate the humid gas within the condenser bag into a condensed fluid and a dehumidified gas. The condensed fluid and the dehumidified gas is then removed from the condenser bag.

Abstract: The present invention relates to immunogenic agents based on trypanosomes, related compositions, and related methods.

Abstract: Recombinant, attenuated parasites are transformed or transfected with nucleic acid molecules which provoke an immunostimulatory and protective response in subjects. Preferably, the parasite is Trypanosoma cruzi, especially strain CL-14, and the transforming nucleic acid molecule encodes for a cancer testis antigen, such as NY-ESO-1.

Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.

Abstract: Ciliate organisms are provided that comprise reduced proteolytic processing in granules. For example, ciliates are provided that lack detectable expression of one or more sortilin (SOR) gene product. Methods for producing such genetically altered ciliates and methods for protein production in a these organisms are also provided.